Franklin Resources Inc. Cuts Stock Position in Stryker Corporation $SYK

Franklin Resources Inc. lowered its stake in Stryker Corporation (NYSE:SYK) by 2.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,198,521 shares of the medical technology company’s stock after selling 93,215 shares during the quarter. Franklin Resources Inc.’s holdings in Stryker were worth $1,124,184,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Czech National Bank lifted its position in Stryker by 3.9% in the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after acquiring an additional 3,366 shares in the last quarter. Davis R M Inc. lifted its position in Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after acquiring an additional 2,512 shares in the last quarter. Kepler Cheuvreux Suisse SA bought a new position in Stryker in the 3rd quarter valued at approximately $27,952,000. Daymark Wealth Partners LLC lifted its position in Stryker by 436.0% in the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock valued at $16,119,000 after acquiring an additional 37,307 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC lifted its position in Stryker by 265.2% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after acquiring an additional 6,774 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP M Kathryn Fink sold 3,500 shares of Stryker stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is owned by company insiders.

Stryker Trading Up 0.0%

Shares of NYSE:SYK opened at $305.71 on Monday. The stock’s 50-day simple moving average is $318.43 and its two-hundred day simple moving average is $345.76. The stock has a market capitalization of $117.20 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 1.93 and a beta of 0.78. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the company earned $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts expect that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analysts Set New Price Targets

Several research firms recently issued reports on SYK. William Blair reaffirmed an “outperform” rating on shares of Stryker in a research report on Thursday, March 5th. Citigroup lowered their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Canaccord Genuity Group lowered their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Leerink Partners lowered their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday. Finally, Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.